Online Oncology Days
Day 3 | Lung Cancer Screening

Online Oncology Days | Day 3 - April 14, 2022 | 7 pm (CEST) / 1 pm (EDT)

Lung Cancer Screening | CT/Mobile Imaging Solutions

The Time is Now

Lung cancer is the leading cause of death among both men and women (1). Approximately 70% of patients have advanced disease, therefore only 15% of patients are still alive 5 years after diagnosis (2). The NELSON trial showed that screening with low-dose CT for a high-risk patient group can help diagnose cancer early in these patients (3). Result, increased chances of successful and curable treatment. Our speakers will present the latest developments in lung cancer screening, will advice on how to overcome barriers in clinical implementation and improve access to screening and will share the newest technology in ultra low dose CT.

This webinar occurs now in the past. The recording is available. Click here to watch it now.
Program
  • Lung Cancer Screening: Where Do We Stand? - Prof. Cornelia M. Schaefer-Prokop
  • Mobile Lung Cancer Screening: Bringing Early Detection to Rural Communities - Prof. Hannah Hazard-Jenkins
  • Improving Lung Cancer Screening: Mobile CT and Liquid Biopsy - Dr. Santiago Viteri
  • Optimizing CT Technology for Lung Cancer Screening - Prof. Mathias Prokop
  • Live Q&A
Why should you attend?
  1. To know the main results of screening trials thus far, especially of the NLST and the Nelson trial
  2. Understand the value of a mobile lung cancer program
  3. Understand the key stakeholders and investigators to make the mobile program work successfully
  4. Understand how optimizing CT technology will benefit lung cancer screening

INFORMATION ON SPEAKERS AND THEIR PRESENTATIONS

sou
Moderator & Speaker: Prof. Cornelia M. Schaefer-Prokop, MD, PhD
Radiologist
Head of Imaging Department
Meander Medical Centre, Radboud University Medical Center (Radboudumc)
Amersfoort, the Netherlands.

Prof. Cornelia Schaefer-Prokop is a radiologist at Meander Medical Centre, Amersfoort, the Netherlands. She has worked as a radiologist in Hannover, Germany (1993-98), AKH Vienna, Austria (1998-2004), AMC Amsterdam (2005-2009) and since 2009 in Meander Medical Centre Amersfoort. For her research, she is affiliated with Radboudumc, Nijmegen. Her main research interests are in computer-aided detection and classification, lung cancer screening and interstitial lung diseases. She is an editorial board member of European Radiology, Journal of Thoracic Imaging and Insights into Imaging and was editorial member of Radiology for many years. She was president of the European Society of Thoracic Imaging (ESTI) in 2014 and is the current president of the Fleischner Society. She is the author of 190 peer-reviewed publications and editor of three books.

Presentation title: Lung Cancer Screening: Where Do We Stand?
The presentation will summarize the results of the two largest randomized screening trials – the NLST and the Nelson trial. Differences between trials and their impact on the results will be outlined. Facts thus far and challenges with respect to eligibility, nodule management, screening interval and screening length will be discussed.

sou
Speaker: Prof. Hannah Hazard-Jenkins, MD, FACS
Associate Professor of Surgery at the department of Surgery WVU School of Medicine
Director of the WVU Cancer Institute
Morgantown, West Virginia, USA

Dr. Hannah Hazard-Jenkins is an Associate Professor and Associate Chair of Cancer Services in the Department of Surgery and the Director of the West Virginia University (WVU) Cancer Institute. She received her medical degree from the WVU School of Medicine and went on to complete her surgical residency at WVU. She continued her surgical training in Chicago with a year fellowship in Breast Diseases at Northwestern University. Dr. Hazard-Jenkins returned to WVU as faculty in the Department of Surgery in 2007. As faculty in the School of Medicine, she held numerous roles culminating in Assistant Dean for Admissions. She subsequently transitioned to cancer center leadership first fulfilling the role of Cancer Service Line Director and then Director of Clinical Services. In January of 2020, she took over the role of Director of the WVU Cancer Institute where she has lead the expansion of regional cancer center sites and supported the development of the LUCAS, a WVU Cancer Institute mobile lung cancer screening unit, with the mission to bring high quality, state of the art cancer care to all that live in West Virginia and the surrounding region.

Presentation title: Mobile Lung Cancer Screening: Bringing Early Detection to Rural Communities
The WVU Cancer Institute worked through our community partners to identify a need for better access to prevention and early detection services for lung cancer. The state has some of the highest rates of tobacco use and smoking in young populations. Developing a mobile program allowed delivery of healthcare to rural parts of our state with the ultimate goal of mitigating some of the cancer outcome disparities of our state and region.

sou
Speaker: Dr. Santiago Viteri, MD
Medical Oncologist and Patient Partner at UOMi Cancer Center
UOMi Cancer Center
Barcelona, Spain

Dr. Santiago Viteri is a medical oncologist, who graduated from the University of Navarra, where he also obtained a specialist degree. During this time he learned to constantly seek new options and treatments for patients and an empathetic and compassionate style of care.
For the last thirteen years, he has worked at the Dr. Rosell Oncology Institute where I have specialized in molecular biology of cancer, personalized medicine, thoracic tumors and clinical research. He started as an assistant but progressively took on management responsibilities for the medical team and became clinical head in charge of a team of 14 oncologists who treated patients in four hospitals in the Barcelona area. He has also developed teaching activities, training specialists from Latin America and Europe and as a speaker at national and international meetings and conferences.

Presentation title: Improving Lung Cancer Screening: Mobile CT and Liquid Biopsy
Several studies have shown that Lung Cancer screening with CT allows detecting the disease at earlier stages, increasing the chances of curative-intent treatment with a positive impact on overall survival. However, the real-life implementation of such programs has been delayed due to costs and health services saturation. Mobile CT-based screening programs and early-stage liquid biopsy are new promising approaches in this setting.

sou
Speaker: Prof. Mathias Prokop, MD, PhD
Radiologist
Chairman of the Department of Radiology
Radboud University Medical Center
Nijmegen, the Netherlands

Prof. Mathias Prokop is a Professor of Radiology and Chairman of the Department of Medical Imaging at the Radboud University Medical Center in Nijmegen, the Netherlands. He is an expert in body imaging with a special focus on multislice CT and cutting-edge techniques. He served on several industry advisory boards as well as various scientific committees, most recently the Fleischner Society. He has been a consultant to the International Atomic Energy Agency (IAEA) on radiation protection in CT. He has received several awards from leading radiological societies including the Radiological Society of North America (RSNA) and the German Roentgen Society. He is a Fellow of the Society of Body CT and Magnetic Resonance (SBCTMR), an honorary member of the Hungarian Society of Radiology, and currently chair of the NVvR (Dutch Radiology Society).

Presentation title: Optimizing CT Technology for Lung Cancer Screening
Population screening for lung cancer requires CT techniques that allow for high-throughput scanning to keep cost affordable, low radiation exposure to minimize risk for screening-induced cancers, and good scan reproducibility to allow for optimum assessment of nodule growth and malignancy prediction. Recent technological advances allow for more automation during scanning, stronger beam filtration for a better compromise between low dose and image quality, and deep learning reconstructions for low-noise images without relevant loss of resolution. With better image quality, volumetric measurements become more reproducible and allow for better assessment of the aggressiveness of lesions, thus providing the basis for a more personalized nodule management.

Scientific Evidence: Lung Cancer Screening | CT

Download scientific evidence on oncology solutions using Canon technologies here.

CT

Karien A M van den Bergh et al.| Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial) | Cancer (2008)
https://pubmed.ncbi.nlm.nih.gov/18484588/

Lucia J M Kroft et al. | Added Value of Ultra-Low-Dose Computed Tomography, Dose Equivalent to Chest x-Ray Radiography, for Diagnosing Chest Pathology | J Thorac Imaging (2019)
https://pubmed.ncbi.nlm.nih.gov/30870305/

Keiichi Nomura et al. | Radiation Dose Reduction for Computed Tomography Localizer Radiography Using an Ag Additional Filter | J Comput Assist Tomogr (2021)
https://pubmed.ncbi.nlm.nih.gov/33475316/

References

  1. Bray F, et al. | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | CA Cancer J Clin (2018)
  2. Siegel RL, et al. | Cancer statistics, 2018 | CA Cancer J Clin (2018)
  3. de Koning HJ, et al. | Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. | N Engl J Med. (2020)

Disclaimers

  • The opinions expressed in this material are solely those of the presenter and not necessarily those of Canon Medical Systems. Canon Medical Systems does not guarantee the accuracy or reliability of the information provided herein.
  • The clinical results, performance and views described in this video/webinar are the experience of the clinician. Results may vary due to clinical setting, patient presentation and other factors. Many factors could cause the actual results and performance of canon Medical’s products to be materially different from any of the aforementioned.
  • Some products shown might not be available in all regulatory jurisdictions, please consult with your local Canon sales office for availability in your region.

Contact Us